Hemodynamic Assessment of Mosaic Ultra Stented Heart Valve in the Aortic Position
Mosaic Ultra Porcine Bioprosthesis - Hemodynamic Study
1 other identifier
observational
43
5 countries
11
Brief Summary
The special fixation methodology of the Mosaic Ultra stented procine bioprosthesis allows valves to maintain their natural leaflet structure and root geometry which prevents leaflet calcification and improves hemodynamic performance and a potential for increased durability. This study will document the hemodynamic performance, as assessed by echocardiographic recordings, at six months post implantation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2006
Longer than P75 for all trials
11 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2006
CompletedFirst Submitted
Initial submission to the registry
May 21, 2007
CompletedFirst Posted
Study publicly available on registry
May 23, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2010
CompletedOctober 29, 2015
October 1, 2015
3.8 years
May 21, 2007
October 28, 2015
Conditions
Keywords
Interventions
All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
Eligibility Criteria
Patients who are eligible for an aortic valve replacement can be enrolled in the study.
You may qualify if:
- Patients who require aortic valve replacement with or without coronary artery bypass grafting or surgical treatment of Atrial Fibrillation.
- Patients who are able to provide informed consent.
You may not qualify if:
- Concomitant procedures other than coronary artery bypass grafting or surgical treatment of Atrial Fibrillation.
- Patients indicated for receiving a mechanical prosthesis.
- Patients who will have a replacement of an existing valve prosthesis.
- Patients refusing or not able to provide informed consent.
- Patients requiring emergency surgery.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (11)
Medinische Universitat Innsbruck
Innsbruck, A-6020, Austria
ZNA Middelheim
Antwerp, Antwerp, 2020, Belgium
Imelda Ziekenhuis
Bonheiden, 2820, Belgium
Hopital St Luc
Bouge, 5004, Belgium
Klinik fur Thorax- Herz und Gefasschirurgie
Dortmund, 44139, Germany
Klinikum der Johann-Wolfgang-Goethe Universitat
Frankfurt Am Mein, 60590, Germany
Albertinen Krankenhaus
Hamburg, 22457, Germany
Soroka University Medical Center
Beersheba, 84101, Israel
Rambam Medical Center
Haifa, 31096, Israel
Hadasit Medical Research Services
Jerusalem, 91120, Israel
U.O. Cardiochirurgia del p.p. Civico
Palermo, 90127, Italy
Study Officials
- STUDY DIRECTOR
Jaak Minten, PhD
Clinical Director Cardiac Surgery Medtronic
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 21, 2007
First Posted
May 23, 2007
Study Start
April 1, 2006
Primary Completion
February 1, 2010
Study Completion
February 1, 2010
Last Updated
October 29, 2015
Record last verified: 2015-10